By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

Delivering on the Promise of Synthetic Data

Replica Analytics News

Replica Analytics Announces New Funding from Nina Capital

Replica Analytics has closed a financing round with Nina Capital. This new funding injection will enable Replica Analytics to continue developing our data synthesis technology and expand our capabilities for creating robust simulators and digital twins. The additional funding will allow our team to accelerate innovation and translate these innovations into easy-to-use products. 

Our Replica Analytics team has developed a strong portfolio of machine learning technologies that can work with real-world health data and create generative models based on them, in a very short period.

About Nina Capital

Nina Capital is a European, sector-focused firm that invests in health technology companies internationally. They invest in companies who marry an in-depth understanding of healthcare system participants' complex network with advanced data science and IT-enabled products and services. They aim to support companies determined to effectively and efficiently serve these participants in Europe and internationally.

About Replica Analytics

Replica Analytics develops unique technologies for generating privacy protective synthetic data that maintains the statistical properties of real data. The Replica Synthesis software provides a full suite of synthetic data generation and evaluation capabilities that can solve multiple grand challenges facing the life sciences industry, and health research in general. Synthetic data enables rapid innovation by accelerating the development of AI models and accelerating clinical studies through data simulations.

For Media Inquiries:

Lisa Brazeau